CTOs on the Move


 
Rokk is a Saint Louis, MO-based company in the Manufacturing sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.rokkgear.com
  • 1224 Fern Ridge Pkwy
    Saint Louis, MO USA 63141
  • Phone: 800.233.6283

Executives

Name Title Contact Details

Similar Companies

New York Mint

New York Mint is a Minneapolis, MN-based company in the Manufacturing sector.

Severn Trent

Severn Trent is a Kissimmee, FL-based company in the Manufacturing sector.

Compact Industries

Compact Industries, Inc. is a Saint Charles, IL-based company in the Manufacturing sector.

QC Industries Conveyors

QC Industries is the leader in low profile belt conveyors through innovative designs that outperform and outlast the competition. More than 25 years ago, our founder took a close, careful look at the needs of our customer base and built a conveyor well

enVVeno

enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company`s lead product, the VenoValve®, is a first-in-class surgical replacement venous valve being developed for the treatment of deep venous Chronic Venous Insufficiency (CVI). The Company is also developing a non-surgical, transcatheter based replacement venous valve for the treatment of deep venous CVI called enVVe™. CVI occurs when valves inside of the veins of the leg become damaged, resulting in the backwards flow of blood (reflux), blood pooling in the lower leg, increased pressure in the veins of the leg (venous hypertension) and in severe cases, venous ulcers that are difficult to heal and become chronic. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the leg, and back to the heart and lungs. The VenoValve is currently being evaluated in the SAVVE U.S. pivotal study and the company is currently waiting for regulatory approval to begin the TAVVE first-in-human trial for enVVe.